These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28286629)

  • 1. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era.
    Nakaya A; Fujita S; Satake A; Nakanishi T; Azuma Y; Tsubokura Y; Hotta M; Yoshimura H; Ishii K; Ito T; Nomura S
    Hematol Rep; 2017 Feb; 9(1):6887. PubMed ID: 28286629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma.
    Talamo G; Farooq U; Zangari M; Liao J; Dolloff NG; Loughran TP; Epner E
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):464-8. PubMed ID: 21156463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets.
    Fiala MA; Dukeman J; Tuchman SA; Keller M; Vij R; Wildes TM
    JCO Clin Cancer Inform; 2017; 1():. PubMed ID: 30547156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology, Staging, and Management of Multiple Myeloma.
    Padala SA; Barsouk A; Barsouk A; Rawla P; Vakiti A; Kolhe R; Kota V; Ajebo GH
    Med Sci (Basel); 2021 Jan; 9(1):. PubMed ID: 33498356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Rare Coexistence of Multiple Myeloma and Polycythemia Vera.
    Landsman A; Barua P; Podrumar A
    J Hematol; 2023 Oct; 12(5):227-230. PubMed ID: 37936979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and therapy of multiple myeloma: current aspects].
    Betticher DC; Cerny T; Fey MF
    Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
    Zagouri F; Kastritis E; Zomas A; Terpos E; Katodritou E; Symeonidis A; Delimpasi S; Pouli A; Vassilakopoulos TP; Michalis E; Giannouli S; Kartasis Z; Christoforidou A; Kokoviadou K; Hatzimichael E; Gika D; Megalakaki C; Papaioannou M; Kyrtsonis MC; Konstantopoulos K; Dimopoulos MA;
    Eur J Haematol; 2017 Nov; 99(5):409-414. PubMed ID: 28675766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma: diagnosis and treatment.
    Nau KC; Lewis WD
    Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study.
    Xu J; Wang M; Shen Y; Yan M; Xie W; Wang B; Liu H; Cen X
    Cancer Manag Res; 2021; 13():1343-1356. PubMed ID: 33603480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
    Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
    Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
    [No Abstract]   [Full Text] [Related]  

  • 13. Smoldering, asymptomatic stage 1, and indolent myeloma.
    Greipp PR
    Curr Treat Options Oncol; 2000 Jun; 1(2):119-26. PubMed ID: 12057049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone Tumors: Multiple Myeloma.
    Kane SF
    FP Essent; 2020 Jun; 493():30-35. PubMed ID: 32573185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and prognosis of multiple myeloma.
    Kyle RA; Elveback LR
    Mayo Clin Proc; 1976 Dec; 51(12):751-60. PubMed ID: 792581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting outcome of patients with multiple myeloma.
    Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
    J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.
    Ludwig H; Kainz S; Schreder M; Zojer N; Hinke A
    EClinicalMedicine; 2023 Apr; 58():101910. PubMed ID: 36969337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.